Pharmaceuticals, Biotechnology and Life Sciences
Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for…
Glenmark signs full commercial-use license for Horizon’s gene-edited CHO cells CAMBRIDGE, England–(BUSINESS WIRE)–Horizon Discovery Group plc (LSE: HZD) (“Horizon”), a…
Glenmark Pharmaceuticals won Orphan Drug Designation from USFDA to its bispecific antibody candidate GBR 1342 for the treatment of patients with multiple myeloma who have received prior therapies.
Glenmark Pharmaceuticals said Tuesday it has bagged the final USFDA’s approval for its generic version of Mylan’s Olux-E Foam, Clobetasol Propionate Foam.
Glenmark Pharmaceuticals got the final approval by the US FDA for its Ranolazine Extended-Release Tablets, generic version of Gilead’s Ranexa.
Indian Glenmark Pharmaceuticals has been granted final approval by the U.S. FDA for Ezetimibe and Simvastatin Tablets, for several doses.
Glenmark Pharmaceuticals has been granted final approval by the FDA for Clindamycin and Benzoyl Peroxide Gel, 1%|5%, a generic version of BenzaClin Gel, 1%|5%, of Valeant Bermuda.
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Telmisartan and Hydrochlorothiazide Tablets .
Apotex, Teva Pharmaceuticals USA, Aurobindo Pharma and Glenmark Pharmaceuticals have won FDA’s approval to market atomoxetine in multiple strengths to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.